Trials / Completed
CompletedNCT03965741
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Prostate Cancer VTE in Sweden: Epidemiology and Anticoagulation Treatment of VTE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 97,765 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. The goal of the study is to gather information how often venous thromboembolism (VTE) occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | Follow clinical administration |
| DRUG | Apixaban(Eliquis) | Follow clinical administration |
| DRUG | Pradaxa (Dabigatran etexilate) | Follow clinical administration |
Timeline
- Start date
- 2019-05-30
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2019-05-29
- Last updated
- 2021-11-30
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03965741. Inclusion in this directory is not an endorsement.